GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OCSE:GMAB) » Definitions » Current Ratio

Genmab AS (OCSE:GMAB) Current Ratio : 5.17 (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genmab AS Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Genmab AS's current ratio for the quarter that ended in Sep. 2024 was 5.17.

Genmab AS has a current ratio of 5.17. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Genmab AS's Current Ratio or its related term are showing as below:

OCSE:GMAB' s Current Ratio Range Over the Past 10 Years
Min: 4.22   Med: 13.08   Max: 23.99
Current: 5.17

During the past 13 years, Genmab AS's highest Current Ratio was 23.99. The lowest was 4.22. And the median was 13.08.

OCSE:GMAB's Current Ratio is ranked better than
61.41% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs OCSE:GMAB: 5.17

Genmab AS Current Ratio Historical Data

The historical data trend for Genmab AS's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Current Ratio Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.88 15.00 14.50 15.48 13.34

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.38 13.34 12.46 5.03 5.17

Competitive Comparison of Genmab AS's Current Ratio

For the Biotechnology subindustry, Genmab AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Current Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Current Ratio falls into.



Genmab AS Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Genmab AS's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=33139/2484
=13.34

Genmab AS's Current Ratio for the quarter that ended in Sep. 2024 is calculated as

Current Ratio (Q: Sep. 2024 )=Total Current Assets (Q: Sep. 2024 )/Total Current Liabilities (Q: Sep. 2024 )
=23699/4585
=5.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab AS  (OCSE:GMAB) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Genmab AS Current Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.